Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients

Table 2 Clinical correlations

Non-parametric correlations	Psoriasin (µg/ml)	Acral ulcers	Skin	ACA	SCL70	DLCO	Lung fibrosis (HRTC)
Rho Spearman
Psoriasin (µg/ml)
r	1.000	0.032	0.019	0.264	−0.150	0.186	0.117
p value	0.0	0.730	0.860	0.002**	0.084	0.045*	0.199
n	134	121	90	133	133	117	122
Acral ulcers
r	0.032	1.000	0.219	0.053	0.093	0.186	0.132
p value	0.730	0.0	0.039*	0.566	0.311	0.053	0.161
n	121	121	89	121	121	109	114
Skin
r	0.019	0.219	−	−0.128	0.089	0.256	0.095
p value	0.860	0.039*	0.0	0.228	0.406	0.019*	0.389
n	90	89	90	90	90	84	85
ACA
r	0.264	0.053	−0.128	1.000	−0.467	−0.164	−0.336
p value	0.002**	0.566	0.228	0.0	0.000**	0.078	0.000**
n	133	121	90	133	133	117	122
SCL70
r	−0.150	0.093	0.089	0.467	1.000	0.265	0.350
p value	0.084	0.311	0.406	0.000**	0.0	0.004**	0.000**
n	133	121	90	133	133	117	122
DLCO
r	0.186	0.186	0.256	−0.164	0.265	1.000	0.451
p value	0.045*	0.053	0.019*	0.078	0.004**	0.0	0.000**
n	117	109	84	117	117	117	113
Lung fibrosis (HRTC)
r	0.117	0.132	0.095	0.336	0.350	0.451	1.000
p value	0.199	0.161	0.389	0.000**	0.000**	0.000**	0.0
n	122	114	85	122	122	113	122

The significant correlations of psoriasin with clinical parameters are in italics
r correlation coefficient, n number of subjects, DLCO diffusion capacity of carbon monoxide, HRCT high resolution computed tomography
Statistical significance level: * p < 0.05
** p < 0.01

ISSN: 1479-5876